Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL vs OXYCODONE AND ASPIRIN (HALF-STRENGTH)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Anesthesia adjunct (induction and maintenance),Analgesia during anesthesia (e.g., for surgery, mechanical ventilation),Management of acute pain (e.g., procedural sedation),Treatment of breakthrough pain in opioid-tolerant patients (via transmucosal formulations),Patient-controlled analgesia (PCA),Epidural or intrathecal analgesia (off-label),Prehospital analgesia for trauma (off-label)
Moderate to moderately severe pain (when combination therapy is appropriate),Off-label: acute pain, chronic pain
25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.
Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults; prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life.
Aspirin: 2-3 hours for low doses, 15-30 hours for anti-inflammatory doses; increased half-life with dose due to saturable metabolism. Oxycodone: Immediate release: 3-4 hours; controlled release: 4.5-5 hours with biphasic absorption.
Fentanyl undergoes extensive hepatic metabolism primarily via CYP3A4 N-dealkylation to norfentanyl (inactive) and other minor metabolites. Approximately 75% of the dose is excreted as metabolites in urine (primarily norfentanyl) and about 9% in feces. Less than 7% is excreted unchanged in urine. The terminal half-life is 3–12 hours, influenced by factors such as hepatic function and age.
Oxycodone is extensively metabolized in the liver via CYP3A4 (N-demethylation to noroxycodone) and CYP2D6 (O-demethylation to oxymorphone). Aspirin is rapidly hydrolyzed to salicylic acid by esterases in the liver and plasma; salicylic acid is conjugated primarily with glycine (salicyluric acid) and glucuronic acid.
Primarily hepatic metabolism to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for ~75% of the dose (10% unchanged), with ~9% excreted in feces.
Aspirin: Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylate); 10% excreted as unchanged salicylate. Oxycodone: Renal (primarily as noroxycodone, oxymorphone, and conjugates); approximately 87% eliminated in urine, 10-14% in feces.
~80–85% bound primarily to albumin and alpha-1-acid glycoprotein.
Aspirin: 80-90% (primarily to albumin, saturable). Oxycodone: 38-45% (primarily to albumin).
Vd: 3–8 L/kg (mean ~4 L/kg), indicating extensive tissue distribution and high lipophilicity.
Aspirin: 0.15-0.2 L/kg. Oxycodone: 2.0-3.7 L/kg; extensive tissue distribution.
Transdermal: ~92%; Transmucosal (buccal): ~50%; Oral transmucosal lozenge: ~33%; Intranasal: ~50–70%; Oral (swallowed): very low due to first-pass metabolism (~30% but variable).
Oral: Aspirin: 80-100% (first-pass hydrolysis to salicylate). Oxycodone: 60-87% (oral); rectal: similar to oral; intravenous: 100%.
GFR 30-50: use with caution, consider dose reduction by 25-50%; GFR <30: avoid or initiate at 50% of usual dose and titrate slowly; anuric patients: significant accumulation, consider alternative.
For GFR 10-50 m L/min: Administer 75% of usual dose at extended intervals (every 8-12 hours). For GFR <10 m L/min: Avoid use due to risk of aspirin accumulation and oxycodone toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with extreme caution, reduce dose by 75%.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Initiate at 50-75% of usual dose and titrate cautiously. Child-Pugh Class C: Avoid use due to risk of oxycodone accumulation and aspirin-induced bleeding.
IV: 1-2 mcg/kg every 2-4 hours; transdermal: not recommended in opioid-naïve children <2 years, start at 12.5 mcg/h if >50 kg; transmucosal: 5-15 mcg/kg as single dose.
Not recommended for pediatric use due to risk of Reye's syndrome from aspirin and lack of safety data for oxycodone in children <18 years.
Start at 50% of usual adult dose, titrate cautiously by 25% increments; avoid transdermal in opioid-naïve elderly; monitor for respiratory depression and cognitive impairment.
Initiate at the low end of dosing range (e.g., one tablet every 6 hours) due to increased sensitivity to opioid effects and risk of aspirin-induced gastrointestinal bleeding. Titrate slowly and monitor renal function.
WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF MEDICATION ERRORS (especially with transmucosal formulations).
Addiction, abuse, and misuse risk; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; cytochrome P450 3A4 interaction with concomitant CNS depressants; risk of Reye syndrome (aspirin) in children and teenagers with viral illnesses.
Life-threatening respiratory depression: risk dose-dependent; monitor respiratory function, especially during initiation and dose escalation.,Addiction, abuse, and misuse: can occur even at recommended doses; screen patients for risk.,Neonatal opioid withdrawal syndrome: prolonged use during pregnancy can result in withdrawal in the newborn.,Interaction with CNS depressants: concomitant use with benzodiazepines or alcohol may cause profound sedation, respiratory depression, coma, and death.,Accidental exposure: especially with transdermal patches; can be fatal.,Risks from use in patients with head injury or increased intracranial pressure: may obscure neurological signs.,Severe hypotension: in patients with compromised blood volume or concomitant use of drugs that depress blood pressure.,Bradycardia and heart block: use with caution in patients with bradyarrhythmias.,Seizures: may exacerbate seizure disorders.,Serotonin syndrome: when used with serotonergic drugs.,Adrenal insufficiency: with prolonged use.,Severe injection site reactions: with injectable formulations.,Risk of medication errors: especially with different formulations (e.g., transdermal vs. transmucosal).
Respiratory depression; drug dependence, abuse, and addiction; CNS depression (additive with other CNS depressants); head injury and increased intracranial pressure; hypotension; seizure disorders; biliary tract disease; impaired renal or hepatic function; history of gastrointestinal bleeding (aspirin); bleeding disorders (aspirin); concurrent use with anticoagulants; Reye syndrome; hypersensitivity to aspirin or NSAIDs; pregnant women (prolonged use may cause neonatal withdrawal).
Hypersensitivity to fentanyl or any component of the formulation,Significant respiratory depression (in unmonitored settings or without resuscitative equipment),Acute or severe bronchial asthma,Paralytic ileus (known or suspected),Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy,Use in opioid-naive patients for transmucosal immediate-release fentanyl (due to risk of fatal respiratory depression),Acute abdomen (relative contraindication; may obscure diagnosis)
Hypersensitivity to oxycodone, aspirin, or any component; severe respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; Reye syndrome (in children/teenagers with viral illness) (aspirin); pregnancy (prolonged use or high doses near term); breastfeeding (oxycodone); severe bleeding disorders (aspirin); concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Avoid grapefruit and grapefruit juice as they can increase fentanyl levels via CYP3A4 inhibition. No other significant food interactions. Maintain adequate hydration to prevent constipation.
Avoid alcohol; may increase risk of liver damage (not applicable) and gastric bleeding. Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (unlikely but caution). Take with food to minimize GI irritation.
First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near term may cause respiratory depression and neonatal abstinence syndrome.
Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; oxycodone may cause neural tube defects. Second trimester: Aspirin may impair fetal renal function; oxycodone risk persists. Third trimester: Aspirin increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage; oxycodone may cause neonatal withdrawal syndrome. Chronic use may lead to neonatal abstinence syndrome.
Fentanyl is excreted into breast milk. Milk-to-plasma ratio is approximately 0.4. Avoid use in lactating women who are poor metabolizers or receive high doses due to risk of infant sedation and respiratory depression.
Oxycodone: M/P ratio approximately 0.5; low levels in milk (0.3-6.9% of maternal weight-adjusted dose), but risk of neonatal sedation and withdrawal. Aspirin: Excreted in milk; M/P ratio ~0.03-0.1; risk of Reye's syndrome with high doses. Both drugs generally contraindicated during breastfeeding due to potential adverse effects in infants.
Clearance of fentanyl is increased during pregnancy, particularly in the third trimester. Dose adjustments may be required; consider increasing dose or frequency. Monitor for efficacy and adjust as needed.
Oxycodone: Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; dose adjustment should be individualized. Aspirin: No pharmacokinetic adjustments recommended; however, due to teratogenicity and fetal risks, use is contraindicated in pregnancy, especially during third trimester. Half-strength formulation not specifically studied; dosage should be based on oxycodone component (typically 2.25 mg) and aspirin component (325 mg) with caution.
Fentanyl is 50-100 times more potent than morphine. Due to high lipophilicity, onset of analgesia is rapid (within 30 seconds IV) but duration is short. Avoid bolus dosing in opioid-naive patients due to risk of chest wall rigidity. Transdermal patches are not indicated for acute pain due to slow onset and prolonged effect. Monitor for respiratory depression, especially in elderly and those with sleep apnea. Tolerance and physical dependence develop with chronic use. Naloxone is the reversal agent.
Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid in patients with severe asthma or COPD. Assess renal function before use, as aspirin can worsen renal impairment. The half-strength formulation contains 325 mg aspirin and 2.25 mg oxycodone HCl per tablet.
Do not drive or operate heavy machinery until you know how fentanyl affects you.,Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Avoid alcohol and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Store fentanyl patches and other formulations safely out of reach of children and pets; used patches should be folded and flushed down toilet.,Do not share this medication with others; it can cause fatal overdose.,Seek emergency medical help if you experience slow/shallow breathing, extreme drowsiness, or difficulty waking up.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; risk of liver damage with acetaminophen-containing products (not applicable here), but aspirin can cause gastrointestinal bleeding.,Avoid alcohol while taking this medication.,Do not crush or chew extended-release tablets (this formulation is immediate-release; advise to swallow whole).,May cause drowsiness or dizziness; avoid driving until you know how the medication affects you.,Seek medical help if you experience signs of allergic reaction (rash, difficulty breathing) or signs of bleeding (black stools, vomiting blood).
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL vs OXYCODONE AND ASPIRIN (HALF-STRENGTH), answered by our medical review team.
FENTANYL is a Opioid Agonist that works by Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.. OXYCODONE AND ASPIRIN (HALF-STRENGTH) is a Opioid Agonist that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL and OXYCODONE AND ASPIRIN (HALF-STRENGTH) depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL is: 25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.. The standard adult dose of OXYCODONE AND ASPIRIN (HALF-STRENGTH) is: Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL and OXYCODONE AND ASPIRIN (HALF-STRENGTH). The risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL is classified as Category D/X. First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near t. OXYCODONE AND ASPIRIN (HALF-STRENGTH) is classified as Category D/X. Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated w. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.